← Back
$ALMR All transactions

Alamar Biosciences, Inc.

▲ BUY
9 / 10

Conviction

$ Value

$4.0M

Shares

235,294

Price

$17

Filed

Apr 20

Why this score? (9/10)
  • Open market buy (+3)
  • Trade value >= $1.0M (+2)
  • % of holdings >= 20% (+2)
  • 10%+ owner (+1)
  • Not a 10b5-1 plan (+1)

Insider

Name

Illumina Innovation Fund II GP, L.L.C. / Naclerio Nicholas

Title

CIK

0001779219

Roles

10% Owner

Transaction Details

Transaction Date

2026-04-20

Code

P

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

507,076

Footnotes

The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1-for-2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the "IPO"). | The securities are held by Illumina Innovation Fund II, L.P. ("IIF II"). Illumina Innovation Fund II GP, L.L.C. ("IIF II GP") is the general partner of IIF II. Nicholas Naclerio ("Mr. Naclerio"), a member of the Issuer's board of directors, is the sole managing member of IIF II GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF II. Each of IIF II GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF II, except to the extent of their respective pecuniary interests therein, if any. | The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1-for-2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO. | Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. | Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85. | The securities are held by Illumina Innovation Fund III, L.P. ("IIF III"). Illumina Innovation Fund III GP, L.L.C. ("IIF III GP") is the general partner of IIF III. Mr. Naclerio, a member of the Issuer's board of directors, is the sole managing member of IIF III GP and may be deemed to have voting, investment and dispositive power with respect to the securities held by IIF III. Each of IIF III GP and Mr. Naclerio disclaim beneficial ownership over the securities held by IIF III, except to the extent of their respective pecuniary interests therein, if any.

Filing Info

Accession No.

0001193125-26-164634

Form Type

4

Issuer CIK

0002104204

Illumina Innovation Fund II GP, L.L.C. / Naclerio Nicholas's History

Date Ticker Type Value
2026-04-20 ALMR C
2026-04-20 ALMR C
2026-04-20 ALMR J
2026-04-20 ALMR J
2026-04-20 ALMR C
2026-04-20 ALMR C
2026-04-20 ALMR $4.0M
2026-04-20 ALMR C $0
2026-04-20 ALMR C $0
2026-04-20 ALMR C $0

Other Insiders at ALMR (90d)

Insider Bought Sold Last
Witney Frank 2026-04-20
Naclerio Nicholas 2026-04-20
Illumina Innovation Fund II GP, L.L.C. 2026-04-20
McAnear Justin J.
Chief Financial Officer
2026-04-20
Chambers Rebecca 2026-04-20
Qiming Corporate GP VI, Ltd. 2026-04-20
White Timothy Ogden
President
2026-04-20
Luo Yuling
Chief Executive Officer
2026-04-20
Chen Shiping
Chief Operating Officer
2026-04-20